Viking Therapeutics (VKTX)
(Delayed Data from NSDQ)
$32.68 USD
+0.11 (0.34%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $32.70 +0.02 (0.06%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth F Momentum F VGM
Fundamental Charts
About Dividend Yield (TTM)
Viking Therapeutics, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
VKTX 32.68 +0.11(0.34%)
Will VKTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for VKTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VKTX
NVO Stock Crashes 22% After 2025 View Cut: More Downside Ahead?
VKTX Stock Down on Wider-Than-Expected Loss in Q2, Nil Sales
VKTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Viking Therapeutics Gears Up for Q2 Earnings: Here's What to Expect
Can Wegovy & Ozempic Drive Another Strong Quarter for Novo Nordisk?
Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views?
Other News for VKTX
Novo Nordisk's Downgraded Expectations - What The Market Is (Obviously) Missing
Benzinga Bulls And Bears: T-Mobile, LendingTree, Molina Healthcare — And Trade Deal Optimism Boosts Markets
Benzinga Bulls And Bears: T-Mobile, LendingTree, Molina Healthcare — And Trade Deal Optimism Boosts Markets
Viking Therapeutics Q2: Confidently Continuing The Recovery
Viking Therapeutics Receives Buy Rating Amid Promising Clinical Developments and Strategic Initiatives